You are here

Goldfinch Bio

The 2023 Biotech Graveyard

Fierce Biotech

Tue, 10/31/23 - 11:34 am

Rubius Therapeutics

Nabriva Therapeutics

Calithera Biosciences

Antios Therapeutics

Magenta Therapeutics

Coda Biotherapeutics

Aristea Therapeutics

Top biotech licensing deals of Q1 2023

BioSpace

Thu, 03/30/23 - 11:03 am

Moderna Therapeutics

Voyager Therapeutics

Neurocrine Biosciences

Karuna Therapeutics

Goldfinch Bio falls from the sky after failing to find a path forward for kidney treatments

Fierce Biotech

Sun, 01/29/23 - 01:22 pm

After its $2B Gilead pact, Goldfinch Bio nabs a cool $100M series B

Fierce Biotech

Tue, 06/30/20 - 10:38 am

Gilead Sciences

Kidney Genome Atlas

Goldfinch Bio, Takeda sign deal for CB1 monoclonal antibody to treat rare and metabolic kidney diseases

Pharmaceutical Business Review

Fri, 10/4/19 - 10:59 pm

CB1 monoclonal antibodies

Gilead strikes deal with biotech Goldfinch Bio to tackle kidney diseases

Marketwatch

Wed, 05/8/19 - 12:37 pm

Gilead Sciences

drug development